We have located links that may give you full text access.
A Long-term follow-up study of 91 cases with ovarian granulosa cell tumors.
Anticancer Research 2014 Februrary
AIM: To evaluate the prognostic factors of ovarian granulosa cell tumors (GCTs) and treatment outcomes in recurrent GCT cases.
PATIENTS AND METHODS: We retrospectively reviewed 91 patients with GCT who were treated in two tertiary Centers between 1989 and 2011.
RESULTS: Eighty patients had stage I tumors, five had stage II, and six had stage III. There were 15 cases of recurrence with a median follow-up time of 58 (3-254) months. Multivariate analysis identified greater tumor size and postoperative residual tumor as independent risk factors for recurrence. Twelve patients underwent secondary surgery at first recurrence. At a median follow-up of 50 (4-185) months from first recurrence, the 5-year survival was 60% for patients with and 100% for those without residual tumor after secondary surgery, respectively (p=0.018, log-rank test).
CONCLUSION: Complete cytoreduction is an important prognostic factor for recurrent cases as well as initial treatment of GCT.
PATIENTS AND METHODS: We retrospectively reviewed 91 patients with GCT who were treated in two tertiary Centers between 1989 and 2011.
RESULTS: Eighty patients had stage I tumors, five had stage II, and six had stage III. There were 15 cases of recurrence with a median follow-up time of 58 (3-254) months. Multivariate analysis identified greater tumor size and postoperative residual tumor as independent risk factors for recurrence. Twelve patients underwent secondary surgery at first recurrence. At a median follow-up of 50 (4-185) months from first recurrence, the 5-year survival was 60% for patients with and 100% for those without residual tumor after secondary surgery, respectively (p=0.018, log-rank test).
CONCLUSION: Complete cytoreduction is an important prognostic factor for recurrent cases as well as initial treatment of GCT.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app